Primary Sjögren’s syndrome: new clinical and therapeutic concepts
Identifieur interne : 001E48 ( Main/Exploration ); précédent : 001E47; suivant : 001E49Primary Sjögren’s syndrome: new clinical and therapeutic concepts
Auteurs : M. Ramos-Casals [Espagne] ; A G Tzioufas [Grèce] ; J. Font [Espagne]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2005-03.
English descriptors
- KwdEn :
- ANA, antinuclear antibodies, CNS, central nervous system, ESR, erythrocyte sedimentation rate, GMN, glomerulonephritis, IFNα, interferon α, PSN, pure sensory neuropathy, RA, rheumatoid arthritis, RP, Raynaud’s phenomenon, SHL, sensorineural hearing loss, SLE, systemic lupus erythematosus, SS, Sjögren’s syndrome, SSc, systemic sclerosis, Sjögren’s syndrome, TIN, tubulointerstitial nephritis, extraglandular features, lymphoma, muscarinic agonists.
- Teeft :
- Abnormal responses, Abnormality, Agonist, Annular erythema, Anticentromere antibodies, Antinuclear antibodies, Arch intern, Arthritis, Arthritis rheum, Asymptomatic patients, Autoimmune, Autoimmune diseases, Autoimmune disorders, Autonomic disturbances, Autonomic neuropathy, Better understanding, Biological agents, Cell lymphoma, Clinical course, Clinical features, Clinical management, Clinical significance, Corticosteroid, Cryoglobulinaemia, Cutaneous, Cutaneous involvement, Cutaneous purpura, Cutaneous vasculitis, Erythrocyte sedimentation rate, Exocrine glands, Extraepithelial expression, Extraglandular, Extraglandular expression, Extraglandular features, Extraglandular involvement, Extraglandular manifestations, First feature, Font, Font table, General population, Haematological abnormalities, Haematological features, Hearing loss, High doses, Higher prevalence, Hydroxychloroquine treatment, Immunosuppressive agents, Indolent subclinical course, Infliximab, Interferon cytokine, Latter group, Lesion, Lung disease, Lupus, Lymphoma, Lymphoma development, Martin martin, Matter lesions, Medium vessel vasculitis, Mesangial proliferative, Moutsopoulos, Multiple sclerosis, Muscarinic, Muscarinic agonists, Muscular involvement, Natural history, Neurological involvement, Neuropathy, Nihon rinsho meneki gakkai kaishi, Older patients, Oral pilocarpine, Oromucosal route, Other hand, Parotid gland, Periepithelial lesions, Pilocarpine, Pilot study, Primary sjogren syndrome, Primary syndrome, Pulmonary disease, Pulmonary function, Pulmonary function tests, Pulmonary involvement, Recent studies, Renal, Renal biopsy, Renal disease, Renal involvement, Rheum, Rheumatol, Rituximab, Salivary, Salivary glands, Semin arthritis rheum, Sensorineural hearing loss, Several studies, Sicca, Sicca features, Sicca symptoms, Significant decrease, Sjogren, Sjogren syndrome, Skopouli, Slow progression, Small airway disease, Small series, Subacute cutaneous lupus erythematosus, Subclinical muscle inflammation, Syndrome, Syndrome patients, System involvement, Systemic lupus erythematosus, Systemic sclerosis, Therapeutic agents, Therapeutic approaches, Therapeutic management, Thorac imaging, Tomography scan pattern, Tubulointerstitial nephritis, Tzioufas, Various studies, Vasculitis, Wide spectrum, Xerostomia.
Abstract
Sicca features are the central clinical manifestations of Sjögren’s syndrome (SS), but recent studies have confirmed that primary SS has a systemic expression, including extraglandular manifestations. Patients with a predominantly extraepithelial expression should be managed differently from patients with predominantly periepithelial or sicca limited disease. In coming years treatment will be based on muscarinic agonists for sicca features and immunosuppressive/biological agents for extraglandular features.
Url:
DOI: 10.1136/ard.2004.025676
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002536
- to stream Istex, to step Curation: 002536
- to stream Istex, to step Checkpoint: 000C98
- to stream Main, to step Merge: 001E62
- to stream Main, to step Curation: 001E48
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Primary Sjögren’s syndrome: new clinical and therapeutic concepts</title>
<author><name sortKey="Ramos Casals, M" sort="Ramos Casals, M" uniqKey="Ramos Casals M" first="M" last="Ramos-Casals">M. Ramos-Casals</name>
</author>
<author><name sortKey="Tzioufas, A G" sort="Tzioufas, A G" uniqKey="Tzioufas A" first="A G" last="Tzioufas">A G Tzioufas</name>
</author>
<author><name sortKey="Font, J" sort="Font, J" uniqKey="Font J" first="J" last="Font">J. Font</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:7E086AA8777483696E4F4BA956FF5638A1F0EC3C</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1136/ard.2004.025676</idno>
<idno type="url">https://api.istex.fr/ark:/67375/NVC-S5C65BGL-G/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002536</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002536</idno>
<idno type="wicri:Area/Istex/Curation">002536</idno>
<idno type="wicri:Area/Istex/Checkpoint">000C98</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000C98</idno>
<idno type="wicri:doubleKey">0003-4967:2005:Ramos Casals M:primary:sjogren:s</idno>
<idno type="wicri:Area/Main/Merge">001E62</idno>
<idno type="wicri:Area/Main/Curation">001E48</idno>
<idno type="wicri:Area/Main/Exploration">001E48</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Primary Sjögren’s syndrome: new clinical and therapeutic concepts</title>
<author><name sortKey="Ramos Casals, M" sort="Ramos Casals, M" uniqKey="Ramos Casals M" first="M" last="Ramos-Casals">M. Ramos-Casals</name>
<affiliation wicri:level="3"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Autoimmune Diseases, Hospital Clinic, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tzioufas, A G" sort="Tzioufas, A G" uniqKey="Tzioufas A" first="A G" last="Tzioufas">A G Tzioufas</name>
<affiliation wicri:level="1"><country xml:lang="fr">Grèce</country>
<wicri:regionArea>Department of Pathophysiology, School of Medicine, University of Athens</wicri:regionArea>
<wicri:noRegion>University of Athens</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Font, J" sort="Font, J" uniqKey="Font J" first="J" last="Font">J. Font</name>
<affiliation wicri:level="3"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Autoimmune Diseases, Hospital Clinic, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2005-03">2005-03</date>
<biblScope unit="volume">64</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="347">347</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>ANA, antinuclear antibodies</term>
<term>CNS, central nervous system</term>
<term>ESR, erythrocyte sedimentation rate</term>
<term>GMN, glomerulonephritis</term>
<term>IFNα, interferon α</term>
<term>PSN, pure sensory neuropathy</term>
<term>RA, rheumatoid arthritis</term>
<term>RP, Raynaud’s phenomenon</term>
<term>SHL, sensorineural hearing loss</term>
<term>SLE, systemic lupus erythematosus</term>
<term>SS, Sjögren’s syndrome</term>
<term>SSc, systemic sclerosis</term>
<term>Sjögren’s syndrome</term>
<term>TIN, tubulointerstitial nephritis</term>
<term>extraglandular features</term>
<term>lymphoma</term>
<term>muscarinic agonists</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Abnormal responses</term>
<term>Abnormality</term>
<term>Agonist</term>
<term>Annular erythema</term>
<term>Anticentromere antibodies</term>
<term>Antinuclear antibodies</term>
<term>Arch intern</term>
<term>Arthritis</term>
<term>Arthritis rheum</term>
<term>Asymptomatic patients</term>
<term>Autoimmune</term>
<term>Autoimmune diseases</term>
<term>Autoimmune disorders</term>
<term>Autonomic disturbances</term>
<term>Autonomic neuropathy</term>
<term>Better understanding</term>
<term>Biological agents</term>
<term>Cell lymphoma</term>
<term>Clinical course</term>
<term>Clinical features</term>
<term>Clinical management</term>
<term>Clinical significance</term>
<term>Corticosteroid</term>
<term>Cryoglobulinaemia</term>
<term>Cutaneous</term>
<term>Cutaneous involvement</term>
<term>Cutaneous purpura</term>
<term>Cutaneous vasculitis</term>
<term>Erythrocyte sedimentation rate</term>
<term>Exocrine glands</term>
<term>Extraepithelial expression</term>
<term>Extraglandular</term>
<term>Extraglandular expression</term>
<term>Extraglandular features</term>
<term>Extraglandular involvement</term>
<term>Extraglandular manifestations</term>
<term>First feature</term>
<term>Font</term>
<term>Font table</term>
<term>General population</term>
<term>Haematological abnormalities</term>
<term>Haematological features</term>
<term>Hearing loss</term>
<term>High doses</term>
<term>Higher prevalence</term>
<term>Hydroxychloroquine treatment</term>
<term>Immunosuppressive agents</term>
<term>Indolent subclinical course</term>
<term>Infliximab</term>
<term>Interferon cytokine</term>
<term>Latter group</term>
<term>Lesion</term>
<term>Lung disease</term>
<term>Lupus</term>
<term>Lymphoma</term>
<term>Lymphoma development</term>
<term>Martin martin</term>
<term>Matter lesions</term>
<term>Medium vessel vasculitis</term>
<term>Mesangial proliferative</term>
<term>Moutsopoulos</term>
<term>Multiple sclerosis</term>
<term>Muscarinic</term>
<term>Muscarinic agonists</term>
<term>Muscular involvement</term>
<term>Natural history</term>
<term>Neurological involvement</term>
<term>Neuropathy</term>
<term>Nihon rinsho meneki gakkai kaishi</term>
<term>Older patients</term>
<term>Oral pilocarpine</term>
<term>Oromucosal route</term>
<term>Other hand</term>
<term>Parotid gland</term>
<term>Periepithelial lesions</term>
<term>Pilocarpine</term>
<term>Pilot study</term>
<term>Primary sjogren syndrome</term>
<term>Primary syndrome</term>
<term>Pulmonary disease</term>
<term>Pulmonary function</term>
<term>Pulmonary function tests</term>
<term>Pulmonary involvement</term>
<term>Recent studies</term>
<term>Renal</term>
<term>Renal biopsy</term>
<term>Renal disease</term>
<term>Renal involvement</term>
<term>Rheum</term>
<term>Rheumatol</term>
<term>Rituximab</term>
<term>Salivary</term>
<term>Salivary glands</term>
<term>Semin arthritis rheum</term>
<term>Sensorineural hearing loss</term>
<term>Several studies</term>
<term>Sicca</term>
<term>Sicca features</term>
<term>Sicca symptoms</term>
<term>Significant decrease</term>
<term>Sjogren</term>
<term>Sjogren syndrome</term>
<term>Skopouli</term>
<term>Slow progression</term>
<term>Small airway disease</term>
<term>Small series</term>
<term>Subacute cutaneous lupus erythematosus</term>
<term>Subclinical muscle inflammation</term>
<term>Syndrome</term>
<term>Syndrome patients</term>
<term>System involvement</term>
<term>Systemic lupus erythematosus</term>
<term>Systemic sclerosis</term>
<term>Therapeutic agents</term>
<term>Therapeutic approaches</term>
<term>Therapeutic management</term>
<term>Thorac imaging</term>
<term>Tomography scan pattern</term>
<term>Tubulointerstitial nephritis</term>
<term>Tzioufas</term>
<term>Various studies</term>
<term>Vasculitis</term>
<term>Wide spectrum</term>
<term>Xerostomia</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Sicca features are the central clinical manifestations of Sjögren’s syndrome (SS), but recent studies have confirmed that primary SS has a systemic expression, including extraglandular manifestations. Patients with a predominantly extraepithelial expression should be managed differently from patients with predominantly periepithelial or sicca limited disease. In coming years treatment will be based on muscarinic agonists for sicca features and immunosuppressive/biological agents for extraglandular features.</div>
</front>
</TEI>
<affiliations><list><country><li>Espagne</li>
<li>Grèce</li>
</country>
<region><li>Catalogne</li>
</region>
<settlement><li>Barcelone</li>
</settlement>
</list>
<tree><country name="Espagne"><region name="Catalogne"><name sortKey="Ramos Casals, M" sort="Ramos Casals, M" uniqKey="Ramos Casals M" first="M" last="Ramos-Casals">M. Ramos-Casals</name>
</region>
<name sortKey="Font, J" sort="Font, J" uniqKey="Font J" first="J" last="Font">J. Font</name>
</country>
<country name="Grèce"><noRegion><name sortKey="Tzioufas, A G" sort="Tzioufas, A G" uniqKey="Tzioufas A" first="A G" last="Tzioufas">A G Tzioufas</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:7E086AA8777483696E4F4BA956FF5638A1F0EC3C |texte= Primary Sjögren’s syndrome: new clinical and therapeutic concepts }}
This area was generated with Dilib version V0.6.33. |